Watson biology: the net profit in 2021 is expected to decrease by 54% - 64% year-on-year
Watson biology announced that in 2021, the company's pre profit was 365 million yuan – 460 million yuan, a year-on-year decrease of 54% - 64%. The company increased its R & D investment in new products and projects, actively promoted domestic and foreign clinical trials of key R & D projects, and the R & D expenses increased by about 256% over the same period of last year.
This text is a result of machine translation.
Related companies：
In-depth
Consumer Staples
hibobi: Unlocking Global Success with Localization Strategy in Diverse Markets
The market in the Middle East has recently gained considerable attention from entrepreneurs worldwide. The hibobi Group, a pioneer in this emerging market, has unique insights in branding and supply chain construction.
Updated 3 hours ago
Watson biology: 13 valent pneumococcal polysaccharide conjugate vaccine has been licensed in Morocco
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 25, 2022 01:02 PM
Briefing Dec 12, 2021 05:48 PM
· Healthcare
Watson biology: Yuxi Watson plans to invest in the production and capacity expansion project of polysaccharide conjugate vaccine, with a total investment of 695 million yuan
Briefing Sep 02, 2021 02:06 PM
· Healthcare
Medical stocks continued to decline in the afternoon, with dongfulong falling more than 15%
Briefing Jul 29, 2021 10:01 AM
Back to Hong Kong, Chinese concept stocks rose collectively, and Wanguo data rose 17.5%
See more
Read next
Insight
In-depth
Insight
In-depth
Technology
WaveFront Ventures: How Can Chinese Companies Win the Global Robotic Race
Mar 24, 2023 02:02 PM
Insight
In-depth
Technology · Analysis
CIRCUE: AI Drives the Revolution of Energy, Leading a Sustainable Future
Mar 23, 2023 12:26 PM